Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
Bright Minds Biosciences (NASDAQ: DRUG) has announced positive preclinical data for its proprietary compound BMB-201, a 5-HT2C/2A mixed agonist. The study, conducted through the National Institute of Health pain screening program, demonstrated that BMB-201 had similar efficacy to morphine in several pain models, including plantar incision and L5/L6 nerve ligation in rats.
Key findings include:
- BMB-201 showed superior reductions in mechanical allodynia and pain-related behaviors compared to morphine in nerve ligation models
- Female rodents experienced significant improvement in pain relief and guarding behavior at higher doses
- The compound's efficacy suggests potential for better pain relief than traditional opioids without associated risks
Bright Minds plans to advance BMB-201 into clinical trials, aiming to position it as a non-opioid alternative for neuropathic pain relief.
Bright Minds Biosciences (NASDAQ: DRUG) ha annunciato dati preclinici positivi per il suo composto proprietario BMB-201, un agonista misto 5-HT2C/2A. Lo studio, condotto attraverso il programma di screening per il dolore del National Institute of Health, ha dimostrato che BMB-201 ha mostrato un'efficacia simile alla morfina in diversi modelli di dolore, tra cui incisione plantare e legatura del nervo L5/L6 nei ratti.
I risultati chiave includono:
- BMB-201 ha mostrato riduzioni superiori nell'allodinia meccanica e nei comportamenti correlati al dolore rispetto alla morfina nei modelli di legatura del nervo
- I roditori femmina hanno mostrato un miglioramento significativo nel sollievo dal dolore e nel comportamento di protezione a dosi più elevate
- L'efficacia del composto suggerisce un potenziale per un sollievo dal dolore migliore rispetto agli oppioidi tradizionali senza i rischi associati
Bright Minds prevede di avanzare BMB-201 verso studi clinici, puntando a posizionarlo come un'alternativa non oppioide per il sollievo dal dolore neuropatico.
Bright Minds Biosciences (NASDAQ: DRUG) ha anunciado datos preclínicos positivos para su compuesto propietario BMB-201, un agonista mixto 5-HT2C/2A. El estudio, realizado a través del programa de cribado del dolor del Instituto Nacional de Salud, demostró que BMB-201 tuvo una eficacia similar a la de la morfina en varios modelos de dolor, incluyendo incisión plantar y ligadura de nervio L5/L6 en ratas.
Los hallazgos clave incluyen:
- BMB-201 mostró reducciones superiores en alodinia mecánica y comportamientos relacionados con el dolor en comparación con la morfina en modelos de ligadura de nervio
- Las roedoras experimentaron una mejora significativa en el alivio del dolor y el comportamiento de protección a dosis más altas
- La eficacia del compuesto sugiere un potencial para un mejor alivio del dolor que los opioides tradicionales sin los riesgos asociados
Bright Minds planea avanzar BMB-201 a ensayos clínicos, con el objetivo de posicionarlo como una alternativa no opioide para el alivio del dolor neuropático.
브라이트 마인드 바이오사이언스(Bright Minds Biosciences) (NASDAQ: DRUG)는 자사의 독점 화합물 BMB-201에 대한 긍정적인 전임상 데이터를 발표했습니다. BMB-201은 5-HT2C/2A 혼합 작용제입니다. 이 연구는 국립보건원(National Institute of Health)의 통증 선별 프로그램을 통해 진행되었으며, BMB-201이 여러 통증 모델에서 모르핀과 유사한 효능을 나타냈습니다. 통증 모델에는 식물 절개 및 쥐의 L5/L6 신경 결찰이 포함됩니다.
주요 발견은 다음과 같습니다:
- BMB-201은 신경 결찰 모델에서 모르핀에 비해 기계적 알로디니아 및 통증 관련 행동의 감소가 우수했습니다
- 여성 설치류는 높은 용량에서 통증 완화 및 보호 행동에서 상당한 개선을 경험했습니다
- 이 화합물의 효능은 전통적인 오피오이드보다 더 나은 통증 완화를 제공할 가능성을 시사합니다
브라이트 마인드는 BMB-201을 임상 시험으로 진행할 계획이며, 신경병성 통증 완화를 위한 비오피오이드 대안으로 자리매김하는 것을 목표로 하고 있습니다.
Bright Minds Biosciences (NASDAQ: DRUG) a annoncé des données précliniques positives pour son composé propriétaire BMB-201, un agoniste mixte 5-HT2C/2A. L'étude, réalisée dans le cadre du programme de dépistage de la douleur de l'Institut national de la santé, a démontré que BMB-201 avait une efficacité similaire à celle de la morphine dans plusieurs modèles de douleur, y compris l'incision plantaire et la ligature du nerf L5/L6 chez les rats.
Les principales conclusions incluent :
- BMB-201 a montré des réductions supérieures de l'allodynie mécanique et des comportements liés à la douleur par rapport à la morphine dans les modèles de ligature du nerf
- Les rongeurs femelles ont connu une amélioration significative du soulagement de la douleur et d'un comportement de protection à des doses plus élevées
- L'efficacité du composé suggère un potentiel pour un meilleur soulagement de la douleur que les opioïdes traditionnels sans les risques associés
Bright Minds prévoit d'avancer BMB-201 dans des essais cliniques, visant à le positionner comme une alternative non-opioïde pour le soulagement de la douleur neuropathique.
Bright Minds Biosciences (NASDAQ: DRUG) hat positive präklinische Daten für seinen proprietären Wirkstoff BMB-201, einen 5-HT2C/2A-Mischagonisten, bekannt gegeben. Die Studie, die im Rahmen des Schmerz-Screening-Programms des National Institute of Health durchgeführt wurde, zeigte, dass BMB-201 eine ähnliche Wirksamkeit wie Morphin aufwies in mehreren Schmerzmodellen, einschließlich plantarer Inzision und L5/L6-Nerventrennung bei Ratten.
Wichtige Ergebnisse sind:
- BMB-201 zeigte überlegene Reduktionen von mechanischer Allodynie und schmerzbezogenem Verhalten im Vergleich zu Morphin in Nerventrennung Modellen
- Weibliche Nagetiere erlebten signifikante Verbesserungen in der Schmerzlinderung und Schutzverhalten bei höheren Dosen
- Die Wirksamkeit des Wirkstoffs deutet auf ein Potenzial für eine bessere Schmerzlinderung hin als traditionelle Opioide ohne die damit verbundenen Risiken
Bright Minds plant, BMB-201 in klinische Studien voranzubringen, mit dem Ziel, es als nicht-opioide Alternative zur Linderung neuropathischer Schmerzen zu positionieren.
- BMB-201 demonstrated similar efficacy to morphine in preclinical pain models
- Superior reductions in mechanical allodynia and pain-related behaviors compared to morphine in nerve ligation models
- Potential for better pain relief than traditional opioids without associated risks of dependency and side effects
- Plans to advance BMB-201 into clinical trials for further evaluation
- None.
Insights
The preclinical data for BMB-201 is highly promising, demonstrating efficacy comparable to morphine in pain models without the associated risks of opioid dependency. This represents a significant advancement in pain management research, particularly for neuropathic pain. The compound's 5-HT2C/2A mixed agonist mechanism offers a novel approach to pain modulation.
Key points to consider:
- BMB-201 showed dose-dependent efficacy in multiple pain models, including plantar incision and L5/L6 nerve ligation.
- The compound demonstrated superior reductions in mechanical allodynia and pain-related behaviors compared to traditional treatments.
- Female rodents showed marked improvement, suggesting potential sex-specific benefits.
- The non-opioid nature of BMB-201 addresses a critical need in pain management, potentially offering a safer alternative to current treatments.
While these results are encouraging, it's important to note that preclinical success doesn't always translate to human trials. The upcoming clinical trials will be important in determining BMB-201's true potential as a pain management solution. Investors should monitor the progress of these trials closely, as positive results could significantly impact Bright Minds Biosciences' market position in the competitive pain management sector.
This preclinical data represents a potentially significant milestone for Bright Minds Biosciences (NASDAQ: DRUG). The positive results for BMB-201 could have substantial implications for the company's future financial performance and market position:
- Market Opportunity: The global neuropathic pain market is projected to reach
$9.8 billion by 2027, presenting a large addressable market for BMB-201 if successful. - Competitive Advantage: BMB-201's non-opioid nature and comparable efficacy to morphine could provide a strong competitive edge in the pain management market.
- Pipeline Value: Positive preclinical data enhances the value of Bright Minds' drug pipeline, potentially attracting investor interest and partnership opportunities.
- Future Revenue Potential: If BMB-201 successfully navigates clinical trials and reaches market approval, it could become a significant revenue driver for the company.
However, investors should remain cautious. With a market cap of only
- BMB-201 demonstrated dose-dependent efficacy in pain models
- BMB-201 demonstrated similar efficacy to morphine in several pain models
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce positive data from the preclinical testing of BMB-201 completed with National Institute of Health pain screening (PSPP) program.
Preclinical pain models included plantar incision and L5/L6 nerve ligation rat models, where the drug candidate was tested along with morphine and gabapentin as positive controls.
Key Highlights from the Study:
In nerve ligation pain models, BMB-201 had similar efficacy to morphine, demonstrating superior reductions in mechanical allodynia and pain-related behaviors.
Female rodents experienced a marked improvement in both pain relief and guarding behavior, with higher doses producing a significant therapeutic effect.
BMB-201’s efficacy suggests that it may provide better pain relief than traditional opioid treatments, without the associated risks of dependency and side effects.
“These findings are a significant step forward in our mission to develop safer and more effective treatments for chronic pain,” said Jan Torleif Pedersen, Chief Scientific Officer of Bright Minds. “The fact that BMB-201 outperforms morphine in preclinical models is a testament to the potential of serotonergic therapies in pain management.”
Next Steps: With these promising preclinical results, Bright Minds plans to advance BMB-201 into clinical trials to further evaluate its safety and efficacy in human subjects. The company aims to position BMB-201 as a non-opioid alternative for neuropathic pain relief, addressing a significant unmet need in the pain management landscape. BMB-201 constitutes a novel MoA for the modulation of pain perception.
This data has been presented at Society for Neuroscience’s annual meeting at the NIH Satellite Forum. The poster is available on www.brightmindsbio.com.
About BMB-201
BMB-201, a selective 5-HT2A/2C receptor agonist, was designed to harness the analgesic potential of serotonin modulation without the hallucinogenic effects commonly associated with 5-HT2A activation. As a prodrug of BMB-A39a, it exhibits minimal activity at the 5-HT2B receptor, ensuring a reduced risk of side effects.
About Bright Minds Biosciences
Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.
Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Forward-Looking Statements
This news release contains “forward-looking information”. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include design, progress, and completion of the BREAKTHROUGH Study, future clinical development of BMB-101, and future intended use or therapeutic benefit of BMB-101 to treat refractory epilepsy disorders. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These factors include the company’s financial position and operational runway, regulatory risk to operating in the pharmaceutical industry, and inaccuracies related to the assumption made by management relating to general availability of resources required to operate the studies noted in this news release. Additional risk factors can also be found in the Company’s public filings under the Company’s SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances, management’s estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
Contact Information
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
Phone: (414)7316422
Email: alex@brightmindsbio.com
Website: www.brightmindsbio.com
FAQ
What is the efficacy of Bright Minds Biosciences' BMB-201 compared to morphine in preclinical pain models?
How did female rodents respond to BMB-201 in the preclinical pain studies?
What are Bright Minds Biosciences' (NASDAQ: DRUG) next steps for BMB-201 after the positive preclinical results?
How does BMB-201 differ from traditional opioid treatments for pain management?
